N@N

Nathan Weinstein Maintained (ATAI) at Strong Buy with Increased Target to $27 on, Aug 17th, 2021

Nathan Weinstein of Aegis Capital, Maintained "Atai Life Sciences N.V." (ATAI) at Strong Buy with Increased Target from $26 to $27 on, Aug 17th, 2021.

Nathan has made no other calls on ATAI in the last 4 months.

There are 7 other peers that have a rating on ATAI. Out of the 7 peers that are also analyzing ATAI, 1 agrees with Nathan's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Brian Abrahams of "RBC Capital" Initiated at Hold and Held Target at $19 on, Tuesday, July 13th, 2021

These are the ratings of the 6 analyists that currently disagree with Nathan

---

• Leonildo Delgado of "Baader Helvea" Initiated at Strong Buy and Held Target at $21 on, Wednesday, July 14th, 2021
• Neena Bitritto-Garg of "Citigroup" Initiated at Strong Buy and Held Target at $26 on, Tuesday, July 13th, 2021
• Ritu Baral of "Cowen & Co." Initiated at Buy on, Tuesday, July 13th, 2021
• Charles Duncan of "Cantor Fitzgerald" Initiated at Buy and Held Target at $45 on, Tuesday, July 13th, 2021
• Esther Hong of "Berenberg" Initiated at Strong Buy and Held Target at $35 on, Tuesday, July 13th, 2021
• Judah Frommer of "Credit Suisse" Initiated at Buy and Held Target at $25 on, Tuesday, July 13th, 2021

Contributing Sources

---